Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 27

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 27
---
 place undue reliance on the forward-looking statements contained in this proxy statement. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. - 17 -

SUMMARY This summary highlights information contained elsewhere in this proxy statement and may not contain all the information that is important to you with respect to the Divestiture, the PIPE Financing, the License Agreement or the ADC Programs. We urge you to read carefully the remainder of this proxy statement, including the attached annexes. We have included page references in this summary to direct you to a more complete description of the topics presented below. Unless otherwise indicated or as the context otherwise requires, all references to “Aadi”, “we”, “us”, or “our” in this proxy statement refer to Aadi Bioscience, Inc., a Delaware corporation. Summary of the Divestiture The Divestiture(see page [●]) On December 19, 2024, Aadi agreed to sell 100% of the outstanding shares of capital stock of Aadi Sub to Kaken, and thereby all or substantially all of Aadi’s assets related to the FYARRO Business. If the Divestiture is completed, Aadi will no longer own Aadi Sub or the FYARRO Business. Parties to the Divestiture(see page [●]) Aadi Bioscience, Inc. Aadi is a precision oncology company making bold choices in applying technology to efficiently deliver improved therapies for people with difficult-to-treat cancers. Aadi is a corporation organized under the laws of the State of Delaware. Shares of Aadi common stock are listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “AADI.” Aadi Subsidiary, Inc. Aadi Subsidiary, Inc. (“Aadi Sub”) is a wholly-owned subsidiary of Aadi and the operating company for the FYARRO Business. Aadi Sub is a corporation organized under the laws of the State of Delaware. KAKEN PHARMACEUTICAL CO., LTD. KAKEN PHARMACEUTICAL CO., LTD. (“Kaken Parent”) develops, produces, and sells pharmaceuticals and agrochemicals. Kaken Parent’s products are mainly for orthopedics and dermatology.